Supplements and Featured Publications
Metastatic Castration-Sensitive Prostate Cancer Treatment Updates
Updates in the Management of Non-Muscle Invasive Bladder Cancer
Treatment Options in Metastatic Castration-Resistant Prostate Cancer
In this K-Cast video series, Neal Shore, MD, describes current standards in the treatment of metastatic castration-resistant prostate cancer (mCRPC) and provides an overview of data from the PROfound trial. Also discussed are genetic testing in mCRPC, the impact of coronavirus disease 2019 on patient care, the role of PARP inhibitors in patients with mCRPC, and considerations for the management of mCRPC.
Clinical Spotlight: Benign Prostatic Hyperplasia
Advertisement
Advertisement
Trending on Urology Times
1
Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men
2
FDA approves first-line Zenflow system for the treatment of BPH
3
FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC
4
FDA approves zoliflodacin for uncomplicated urogenital gonorrhea
5
